1. Gene-dose-dependent reduction of Fshr expression improves spatial memory deficits in Alzheimer's mice.
- Author
-
Korkmaz F, Sims S, Sen F, Sultana F, Laurencin V, Cullen L, Pallapati A, Liu A, Chen R, Rojekar S, Pevnev G, Cheliadinova U, Vasilyeva D, Burganova G, Macdonald A, Saxena M, Goosens K, Rosen CJ, Barak O, Lizneva D, Gumerova A, Ye K, Ryu V, Yuen T, Frolinger T, and Zaidi M
- Abstract
High post-menopausal levels of the pituitary gonadotropin follicle-stimulating hormone (FSH) are strongly associated with the onset of Alzheimer's disease (AD). We have shown recently that FSH directly activates the hippocampal FSH receptors (FSHRs) to drive AD-like pathology and memory loss in mice. To unequivocally establish a role for FSH in memory loss, we depleted the Fshr on a 3xTg background and utilized Morris Water Maze to study deficits in spatial memory. 3xTg;Fshr
+/+ mice displayed impaired spatial memory at 5 months of age. The loss of memory acquisition and retrieval were both rescued in 3xTg;Fshr-/- mice and, to a lesser extent, in 3xTg;Fshr+/- mice-documenting clear gene-dose-dependent prevention of spatial memory loss. Furthermore, at 5 and 8 months, sham-operated 3xTg;Fshr-/- mice showed better memory performance during the learning and/or retrieval phases, further suggesting that Fshr deletion prevents age-related progression of memory deficits. This prevention was not seen when mice were ovariectomized, except in the 8-month-old 3xTg;Fshr-/- mice. There was also a gene-dose-dependent reduction mainly in the amyloid β40 isoform in whole brain extracts. Finally, serum FSH levels <8 ng/mL in 16-month-old APP/PS1 mice were associated with better retrieval of spatial memory. Collectively, the data provide compelling genetic evidence for a protective effect of inhibiting FSH signaling on the progression of spatial memory deficits in mice and lay a firm foundation for the use of an FSH-blocking agent for the early prevention of memory loss in post-menopausal women., Competing Interests: Competing interests MZ is inventor on issued and pending patients on the use of FSH as a target for osteoporosis, obesity and Alzheimer’s disease. MZ, SR and TY are inventors on a pending patent on an FSH antibody that is formulated at ultrahigh concentration. The patents will be held by the Icahn School of Medicine at Mount Sinai, and MZ, SR and TY would be recipient of royalties, per institutional policy. The other authors declare no competing financial interests. Ethics approval All methods were performed in accordance with the relevant guidelines and regulations. Animal handling and use were compliant with the National Institutes of Health’s Guide for the Care and Use of Laboratory Animals, and approved by the Icahn School of Medicine at Mount Sinai Institutional Animal Care and Use Committee (IACUC Approval # 2018-0047)., (© 2024. The Author(s), under exclusive licence to Springer Nature Limited.)- Published
- 2024
- Full Text
- View/download PDF